342597-54-0

Basic information

• Product Name: 5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazole-3-thiol
• Synonyms: 5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazole-3-thiol
• CAS NO: 342597-54-0
• Molecular Weight: 297.381
• Mol File: 342597-54-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazole-3-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazole-3-thiol(342597-54-0)
• EPA Substance Registry System: 5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazole-3-thiol(342597-54-0)

Safety Data

• Hazardous Substances Data: 342597-54-0(Hazardous Substances Data)

Upstream product

• 57676-49-0 2-(4-methoxyphenyl)acetic acid hydrazide 
• 103-72-0 phenyl isothiocyanate 
• 14062-18-1 ethyl p-methoxyphenylacetate 
• 104-01-8 4-Methoxyphenylacetic acid 
• 61904-70-9 C₁₆H₁₇N₃O₂S 

Downstream Products

• 893686-69-6 5-(4-methoxybenzyl)-4-phenyl-3-benzylsulfanyl-4H-1,2,4-triazole 
• 874798-05-7 2-[5-(4-methoxybenzyl)-4-phenyl-4H-1,2,4-triazol-3-ylsulfanyl]acetic acid 
• 898608-06-5 3-(4-methoxybenzyl)-4-phenyl-1-morpholinomethyl-1H-1,2,4-triazole-5(4H)-thione 

Relevant articles and documents

Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in?vitro biological evaluation, molecular docking and in silico ADME-T studies

Synthesis of twenty nine new 1,2,4-triazoles and some derived thiazolothiadiazoles (structurally-relevant to some reported triazoles with anticancer and/or Cdc25A/B inhibitory activities) is described in this study. The obtained NCI's in vitro antitumor data revealed that five analogs (12, 15, 18, 19 and 22) displayed considerable tumor percentage growth inhibitory activity (GI%), among which the analog 18 possessed a special antitumor potential and spectrum. Additionally, the same five analogs showed a marginal GI effect on the normal breast epithelial cell line MCF-10A indicating higher selectivity towards cancer cells. The same active analogs 12, 15, 18, 19 and 22 were further assessed for their in vitro Cdc25A/B phosphatase inhibitory activity (a possible antitumor target), where 18 and 22 displayed a distinctive inhibitory affinity towards the Cdc25B isozyme (6.7 and 8.4 μM, respectively). Docking of 12, 15, 18, 19 and 22 with the active site of human Cdc25B phosphatase enzyme demonstrated superior binding profile by the top-scoring analog 18 relative to a reported Cdc25 phosphatase ligand. In silico calculations of molecular properties revealed that all of the active compounds comply with Lipinski's RO5 and Veber's criteria for good bioavailability suggesting good drug-likeness upon oral administration with a predicted high safety profile.